Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Oncolytics Biotech® Inc. (Nasdaq: ONCY) Just Landed At The Top Of Our Watchlist This Morning, Monday, July 13, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At ONCY While It’s Still Early… July 13, 2026 Dear Reader, Monday morning is here and ONCY is exactly where we said it would be — at the top of our watchlist. We laid out the full case last night on Oncolytics Biotech® Inc. (Nasdaq: ONCY), and the core of it hasn't changed: this company has reached agreement with the FDA on two separate registrational pathways, one in anal cancer and one in colorectal cancer, while delivering colorectal cancer survival data that runs more than double the current standard of care. That is not a minor distinction. That is the kind of clinical differentiation that tends to get noticed. Its lead immunotherapy candidate pelareorep has been generating data that serious biotech followers should not be ignoring as the second half of 2026 gets underway. You have time before the open. Take a look at ONCY now. 
But keep in mind, ONCY appears to be flying under the radar while it’s currently trending below $1. Meanwhile, several analysts covering ONCY have set targets that stand significantly above its recent range. In a report published on Friday, Maxim Group analyst Jason McCarthy listed ONCY with a $3 target. And David Bautz, PhD from Zacks SCR has set a $6 valuation on ONCY The Clinical Data Behind ONCY Analyst coverage is only one part of what has placed ONCY on our radar. The more important part is the clinical data supporting pelareorep’s development. The case here is built on facts: pelareorep just delivered a 33% objective response rate in second-line KRAS-mutant colorectal cancer with a median overall survival of 27 months — compared to approximately 11.2 months for the current standard of care. That same regimen produced a median progression-free survival of 16.6 months versus 5.7 months for standard treatment. Those numbers are hard to overlook. There are three separate programs in motion at ONCY right now — colorectal cancer, anal cancer, and pancreatic cancer — each backed by clinical data, each with a defined regulatory path. The REO 033 randomized Phase 2 colorectal cancer study launched in March 2026, with preliminary data expected before year-end. In April 2026, the company reached agreement with the FDA on the design of a registrational anal cancer trial expected to enroll well under 100 subjects. 
And at ASCO 2026, ONCY presented translational data confirming pelareorep’s mechanism across gastrointestinal tumors. Before we break down what ONCY has built and why it’s on our radar this weekend, here’s a quick look at the company’s foundation. Inside Oncolytics Biotech San Diego-based Oncolytics Biotech® Inc. (Nasdaq: ONCY) is a clinical-stage immunotherapy company developing pelareorep — commonly referred to as “pela” — as an intravenously administered immunotherapy agent for gastrointestinal and other solid tumors. Pela is derived from the naturally occurring Reovirus and is designed to work by evading immune neutralization in the bloodstream, delivering directly to tumor tissue, and triggering both innate and adaptive immune responses that convert cold tumors into immune-active environments. The company’s pipeline is focused on GI oncology indications — colorectal cancer, anal cancer, and pancreatic cancer — with clinical data now supporting registration-enabling programs in two of those three settings. ONCY is led by CEO Jared Kelly, a transactional executive with over 50 deals in his history, including the $2B Ambrx sale to Johnson & Johnson. CMO Thomas Heineman, M.D., Ph.D. brings nearly 30 years in dr-ug development with expertise spanning virology and oncology. CBO Andrew Aromando contributes over 30 years in oncology portfolio optimization. ONCY’s Position Within a $150B Immuno-Oncology Market
Pelareorep competes within the global cancer immunotherapy market, valued at over $136B in 2025 and projected to surpass $150B in 2026 — a sector expanding at a CAGR of 10.42% through 2035 as RAS-mutant cancers — among the hardest to treat — become a central focus for next-generation targeted and immune-based approaches. Colorectal cancer alone accounts for over 150,000 new diagnoses annually in the United States, with RAS mutations present in approximately 45–50% of cases. The microsatellite-stable (MSS) subtype — which is immunotherapy-resistant under current checkpoint inhibitor approaches — represents the bulk of that patient population. Pela’s ability to generate immune responses in MSS-RAS-mutant colorectal cancer, a setting where checkpoint inhibitors have largely failed, positions it differently from most agents currently in development. Anal cancer represents a smaller but highly underserved indication with no broadly approved second-line standard of care, making the accelerated approval pathway Oncolytics is pursuing particularly relevant. In pancreatic cancer, where five-year survival rates remain below 13%, any agent that can demonstrate meaningful response rates in combination with chemotherapy and checkpoint inhibition draws immediate attention from both clinical and commercial audiences. What's Been Happening at ONCY
June 16, 2026 — Oncolytics Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
The USPTO issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044. A previously filed method-of-use patent application — if issued — would extend protection into 2046. Oncolytics also announced plans to file additional patents in 2026 across therapeutic applications, treatment settings, and combination approaches, further building out the pelareorep intellectual property estate ahead of potential commercialization. June 2, 2026 — Oncolytics Appoints Steve Glover to Board of Directors and Promotes John McAdory to Chief Operating Officer
Glover brings extensive public company and transaction experience, including serving as Chairman of Ambrx Biopharma during its $2B acquisition by Johnson & Johnson. McAdory, who joined Oncolytics earlier in 2026 from CG Oncology, will oversee clinical operations, preclinical R&D, and strategic partnerships in his expanded role. June 1, 2026 — Oncolytics Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Preclinical data showed pelareorep in combination with RAS inhibitors delivered greater anti-tumor activity than either agent alone — opening a potential next-generation combination strategy in KRAS-driven cancers. June 2026 — Oncolytics Presents at ASCO 2026, Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
Translational analyses confirmed that pelareorep expands pre-existing tumor-reactive immune cells and triggers measurable increases in KRAS-specific T-cell clones in pancreatic cancer patients. April 2026 — Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
A Type C FDA meeting resulted in alignment on the design of a pivotal single-arm study to support approval of pelareorep in patients with unresectable metastatic squamous cell carcinoma of the anal canal — a program built on a 30% objective response rate in second-line or later SCAC, more than double the 13.8% ORR of the current approved second-line treatment. April 2026 — Oncolytics Presents New Mechanistic and Translational Data at AACR 2026
Data from the GOBLET pancreatic cancer study showed a 62% objective response rate in first-line metastatic pancreatic ductal adenocarcinoma. March 2026 — Oncolytics Launches Randomized Colorectal Cancer Study — REO 033
The company initiated REO 033, a randomized Phase 2 study comparing pelareorep plus bevacizumab and FOLFIRI against bevacizumab and FOLFIRI alone in second-line RAS-mutant MSS metastatic colorectal cancer. Preliminary data is expected before year-end 2026. The launch followed the FDA's Fast Track Designation for pelareorep in that same indication. 7 Reasons Why ONCY is Topping Our Watchlist This Morning—Monday, July 13, 2026…
1. Analyst Coverage: ONCY continues receiving coverage from analysts, including a recent $3 target from Maxim Group and a $6 valuation from Zacks SCR.
2. Upcoming Potential Catalyst: ONCY launched the randomized REO 033 Phase 2 colorectal cancer study in March 2026, with preliminary data expected before year-end.
3. FDA Progress: ONCY has reached agreement with the FDA on registrational pathways in both colorectal cancer and anal cancer, marking two significant regulatory milestones across its clinical pipeline. 4. Strong Survival: ONCY reported a median overall survival of 27 months in second-line KRAS-mutant colorectal cancer, compared to approximately 11.2 months for the current standard of care. 5. Three Programs: ONCY is advancing clinical programs in colorectal cancer, anal cancer, and pancreatic cancer, with each supported by clinical data and ongoing development. 6. Patent Protection: ONCY recently secured a new U.S. patent protecting its proprietary pelareorep manufacturing process into 2044, with additional patent filings planned. 7. $150B Market: ONCY is developing pelareorep within the global cancer immunotherapy market, valued at USD 136.39B in 2025 and projected to surpass $150B in 2026. Take A Look At ONCY While It’s Still Early…
Multiple developments are now beginning to connect at ONCY. FDA progress across two registrational programs, encouraging colorectal cancer survival data, a randomized Phase 2 study already underway, continued analyst coverage, expanding patent protection, and a pipeline spanning three gastrointestinal cancer indications all contribute to why this company has climbed to the top of our watchlist. With pelareorep advancing within a global cancer immunotherapy market projected to surpass $150B in 2026, we'll be watching closely to see how the story continues developing in the months ahead. We have all eyes on ONCY this morning. Take a look at ONCY while it’s still early. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends |
No comments:
Post a Comment